Proteogenix는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.

제품 설명 

SARS-CoV-2 Spike full length (trimer form), D614

제품 번호

PX-COV-P049

제품 특징

Description of SARS-CoV-2 Spike full length (trimer form), D614

General information on SARS-CoV-2 Spike full length (variant 1), D614

SARS-CoV-2 is an enveloped positive-sense single-stranded RNA virus from the Coronavirus family. First identified in the Wuhan province (China) in December 2019 as the etiological agent of the COVID-19 disease, SARS-CoV-2 was soon classified as a pandemic strain that probably originated from animal reservoirs (zoonotic origin). The genome of the strain was shortly obtained allowing the design of fast response platforms for diagnostics and biotherapeutic/vaccine development. Like SARS-CoV-1, the new strain was found to adhere to human epithelial cells via its transmembrane structural protein known as the spike protein. The spike, one of the most abundant structural proteins on the envelope of this virus, is a complex and trimeric structure containing an N-terminal domain (S1 subunit) responsible for binding the human receptor ACE2 and a C-terminal domain (S2 subunit) responsible for forming the fusion core that mediates membrane fusion and viral internalization. The two units are linked by a furin cleavage site easily cleaved by ubiquitous proteases. This property has made the production of stable full-length forms of the spike protein rather challenging.
Several strategies can be used to overcome this limitation, at ProteoGenix, the full-length recombinant spike protein of SARS-CoV-2 was stabilized before its expression with targeted mutations to the furin cleavage site, considerably increasing its shelf-life without altering its original function. The stabilized variant can thus be used for studies that aim to further unravel the mechanism of infection in this new strain, but also serve in the development of diagnostic tools, targeted treatments, and vaccines.
The D614 variant of the spike was the dominant form of the protein during the early months of the epidemic when a sudden mutation in early March resulted in this position started gaining relevance (D614G, corresponding to a G-to-A base change at position 23,403 in the Wuhan reference strain). Data shows that the G614 variant, also known as the “G” clade, was first detected in Europe and then spread across the globe to become the dominant variant over a single month. In this context, the original D614 remains useful for comparative studies and further elucidation of SARS-CoV-2 mechanisms of infections.

Related products:

• Spike, full-length protein variant G614, trimeric
• Spike, full-length protein variant G614, monomeric
• Spike protein S2
• RBD domain

QC & Validation Data

SDS-PAGE for SARS-CoV-2 Spike full length (trimer form), D614 Recombinant proteins

Publications

- Sandra Barroso-Arévalo, Lidia Sánchez-Morales, Mercedes Domínguez, Teresa García-Seco, María A. Risalde, Ignacio García-Bocanegra, Lucas Domínguez, José M. Sánchez-Vizcaíno, Research in Veterinary Science,Volume 148,(2022) A subunit vaccine candidate based on the Spike protein of SARS-CoV-2 prevents infectious virus shedding in cats

- Jaśmina Bałaban, Mateusz Wierzbicki, Marlena Zielińska-Górska, Malwina Sosnowska, Karolina Daniluk, Sławomir Jaworski, Piotr Koczoń, Dominik Cysewski, André Chwalibog & Ewa Sawosz (2023) Graphene Oxide Decreases Pro-Inflammatory Proteins Production in Skeletal Muscle Cells Exposed to SARS-CoV-2 Spike Protein, Nanotechnology, Science and Applications, 16:, 1-18, DOI: 10.2147/NSA.S391761

ProteoGenix의 모든 제품들을 만나보세요!

• Proteins
• 
  
• Primary antibodies
• 
  
• Secondary antibodies
• 
  
• ELISA assay kits
• 
  
• Cell separation media
• 
  
• Other products

Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"